It is estimated that 20% of malignancies worldwide can be attributed to infections, i.e. about 1.2 million cases per year. A typical example of the association between bacterial infection and gastrointestinal malignancies is Helicobacter pylori infection with both gastric cancer and mucosa-associated lymphoid tissue lymphoma. Bacteria are an important component of the human body. The human intestine contains >500 different types of microorganisms, the ‘gut microbiota’, that play important functions such as energetic metabolism, proliferation and survival of epithelial cells, and protection against pathogens. Chronic alteration of intestinal microbiota homeostasis, ‘dysbiosis’, could promote many diseases, including cancer. The mechanisms by which bacteria may induce carcinogenesis include chronic inflammation, immune evasion, and immune suppression. There are three effector pathways of T helper (Th) cell differentiation: Th1 responses promoted by procarcinogenic signal transducer and activator of transcription (Stat)1 and Stat4 signaling, Th2 responses promoted by Stat6 signaling, and Th17 responses promoted by Stat3 signaling. Interestingly, Th1 responses, driven by IL-12 and characterized by IFN-γ production, are typically anticarcinogenic, whereas Th17 responses are activated in various cancers. Furthermore, a T regulatory response, driven by IL-10 and TGF-β, counterbalances the proinflammatory effect of Th17 responses. Elevated numbers of T regulatory cells suppress the innate and adaptive immune responses, thereby contributing to tumor progression. The emerging relationship between gut microbiota and cancer has prompted new ways of thinking about cancer prevention and has led to the development of noninvasive diagnostic tests and innovative treatments, such as with probiotics. However, although in vitro and animal model studies suggest a protective anticancer effect of probiotics, the results of human epidemiological studies are controversial.

Keywords:
Gut microbiota, Innate immunity, Adaptive immunity, Colorectal cancer, Probiotics
1.
de Martel C, Franceschi S: Infections and cancer: established associations and new hypotheses. Crit Rev Oncol Hematol 2009;70:183–194.
2.
Tlaskalová-Hogenová H, Stěpánková R, Kozáková H, Hudcovic T, Vannucci L, Tučková L, Rossmann P, Hrnčíř T, Kverka M, Zákostelská Z, Klimešová K, Přibylová J, Bártová J, Sanchez D, Fundová P, Borovská D, Srůtková D, Zídek Z, Schwarzer M, Drastich P, Funda DP: The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 2011;8:110–120.
3.
Round JL, Mazmanian SK: The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009;9:313–323.
4.
Terzić J, Grivennikov S, Karin E, Karin M: Inflammation and colon cancer. Gastroenterology 2010;138:2101–2114.
5.
Neish AS: Microbes in gastrointestinal health and disease. Gastroenterology 2009;136:65–80.
6.
Ioannou S, Voulgarelis M: Toll-like receptors, tissue injury, and tumourigenesis. Mediators Inflamm 2010;pii:581837.
7.
Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R: Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell 2004;118:229–241.
8.
Pull SL, Doherty JM, Mills JC, Gordon JI, Stappenbeck TS: Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci USA 2005;102:99–104.
9.
Fukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, Xu R, Inoue H, Arditi M, Dannenberg AJ, Abreu MT: Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology 2006;131:862–877.
10.
Boraska Jelavić T, Barisić M, Drmic Hofman I, Boraska V, Vrdoljak E, Peruzović M, Hozo I, Puljiz Z, Terzić J: Microsatelite GT polymorphism in the Toll-like receptor 2 is associated with colorectal cancer. Clin Genet 2006;70:156–160.
11.
Zhang G, Ghosh S: Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest 2001;107:13–19.
12.
Izcue A, Coombes JL, Powrie F: Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol 2009;27:313–338.
13.
Weaver CT, Hatton RD, Mangan PR, Harrington LE: IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821–852.
14.
Dunn GP, Koebel CM, Schreiber RD: Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836–848.
15.
Buonocore S, Ahern PP, Uhlig HH, Ivanov II, Littman DR, Maloy KJ, Powrie F: Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 2010;464:1371–1375.
16.
Ji Y, Zhang W: Th17 cells: positive or negative role in tumor? Cancer Immunol Immunother 2010;59:979–987.
17.
Yang ZZ, Ansell SM: The role of Treg cells in the cancer immunological response. Am J Immunol 2009;5:17–28.
18.
Greer JB, O’Keefe SJ: Microbial induction of immunity, inflammation, and cancer. Front Physiol 2011;1:168.
19.
Reddy BS, Mastromarino A, Wynder EL: Further leads on metabolic epidemiology of large bowel cancer. Cancer Res 1975;35: 3403–3406.
20.
Vannucci L, Stepankova R, Kozakova H, Fiserova A, Rossmann P, Tlaskalova-Hogenova H: Colorectal carcinogenesis in germ-free and conventionally reared rats: different intestinal environments affect the systemic immunity. Int J Oncol 2008;32:609–617.
21.
Rakoff-Nahoum S, Medzhitov R: Role of Toll-like receptors in tissue repair and tumorigenesis. Biochemistry (Mosc) 2008;73:555–561.
22.
Gold JS, Bayar S, Salem RR: Association of Streptococcus bovis bacteremia with colonic neoplasia and extracolonic malignancy. Arch Surg 2004;139:760–765.
23.
Ellmerich S, Scholler M, Duranton B, et al: Promotion of intestinal carcinogenesis by Streptococcus bovis. Carcinogenesis 2000;21:753–756.
24.
Sears CL, Islam S, Saha A, Arjumand M, Alam NH, Faruque AS, Salam MA, Shin J, Hecht D, Weintraub A, Sack RB, Qadri F: Association of enterotoxigenic Bacteroides fragilis infection with inflammatory diarrhea. Clin Infect Dis 2008;47:797–803.
25.
Toprak NU, Yagci A, Gulluoglu BM, Akin ML, Demirkalem P, Celenk T, Soyletir G: A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin Microbiol Infect 2006;12:782–786.
26.
Wu S, Morin PJ, Mauyo DJIK, Sears C: Bacteroides fragilis enterotoxin induces c-myc expression and cellular proliferation. Gastroenterology 2003;124:392–400.
27.
Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, Huso DL, Brancati FL, Wick E, McAllister F, Housseau F, Pardoll DM, Sears CL: A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009;15:1016–1022.
28.
Cuevas-Ramos G, Petit CR, Marcq I, Boury M, Oswald E, Nougayrède JP: Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci USA 2010;107:11537–11542.
29.
Gueimonde M, Ouwehand A, Huhtinen H, Salminen E, Salminen S: Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer, diverticulitis and inflammatory bowel disease. World J Gastroenterol 2007;13:3985–3989.
30.
Shen XJ, Rawls JF, Randall T, Burcal L, Mpande CN, Jenkins N, Jovov B, Abdo Z, Sandler RS, Keku TO: Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut Microbes 2010;1:138–147.
31.
Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, Langella P, Corthier G, Tran Van Nhieu J, Furet JP: Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 2011;6:e16393.
32.
Yu LX, Yan HX, Liu Q, Yang W, Wu HP, Dong W, Tang L, Lin Y, He YQ, Zou SS, Wang C, Zhang HL, Cao GW, Wu MC, Wang HY: Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 2010;52:1322–1333.
33.
Rao VP, Poutahidis T, Ge Z, et al: Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res 2006;66:7395–7400.
34.
Rao VP, Poutahidis T, Ge Z, et al: Proinflammatory CD4+ CD45RBhi lymphocytes promote mammary and intestinal carcinogenesis in ApcMin/+ mice. Cancer Res 2006;66:57–61.
35.
Rao VP, Poutahidis T, Fox JG, Erdman SE: Breast cancer: should gastrointestinal bacteria be on our radar screen? Cancer Res 2007;67:847–850.
36.
Liong MT: Roles of probiotics and prebiotics in colon cancer prevention: postulated mechanisms and in-vivo evidence. Int J Mol Sci 2008;9:854–863.
37.
Malhotra SL: Dietary factors in a study of colon cancer from cancer registry, with special reference to the role of saliva, milk and fermented milk products and vegetable fibre. Med Hypotheses 1977;3:122–134.
38.
Peters RK, Pike MC, Garabrant D, Mack TM: Diet and colon cancer in Los Angeles County, California. Cancer Causes Control 1992;3:457–473.
39.
Young TB, Wolf DA: Case-control study of proximal and distal colon cancer and diet in Wisconsin. Int J Cancer 1988;42:167–175.
40.
Kampman E, Giovannucci E, van’t Veer P, Rimm E, Stampfer MJ, Colditz GA, Kok FJ, Willett WC: Calcium, vitamin D, dairy foods and the occurrence of colorectal adenomas among men and women in two prospective studies. Am J Epidemiol 1994;139:16–29.
41.
Kampman E, Goldbohm RA, van den Brandt PA, van’t Veer P: Fermented dairy products, calcium and colorectal cancer in the Netherlands cohort study. Cancer Res 1994;54:3186–3190.
42.
Capurso G, Marignani M, Delle Fave G: Probiotics and the incidence of colorectal cancer: when evidence is not evident. Dig Liver Dis 2006;38(suppl 2):S277–S282.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.